

HEDIS MEASURE OVERVIEW

Osteoporosis Management in Women Who Had a Fracture (OMW)

Please note that the information offered in this flyer is based on Healthcare Effectiveness Data and Information Set (HEDIS®) technical specifications. It is not meant to replace your clinical judgment.

Measure description

Percentage of women 67–85 years old who suffered a fracture* between July 1 of the prior year and June 30 of the current measurement year and had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

* Fractures of face, skull, fingers or toes are excluded.





Who is included in the OMW measure?

Women 67–85 years old who suffered a fracture between July 1 of the prior year and June 30 of the current measurement year.

- Patients will be removed from the eligible population if they have had a:
 - BMD test within 24 months prior to the fracture
 - Dispensed prescription to treat osteoporosis or osteoporosis medication therapy within 12 months before the fracture

Exclusions

- Patients in hospice, using hospice services or receiving palliative care
- Patients who died anytime during the measurement year
- Patients 67 years old and older living long-term in an institutional setting or enrolled in an Institutional Special Needs Plan (I-SNP)
- Patients 67–80 years old with frailty **and** advanced illness, as well as those 81 years old and older with frailty only with at least two indications of frailty



Humana®

Satisfying the OMW measure

Any one of the following services performed for eligible members will satisfy the measure requirement:

- Within six months (180 days) of the fracture date or date of discharge (if hospitalized for fracture):
 - A BMD test in any setting, including tests administered during inpatient stay for fracture
 - Dispensed osteoporosis medication therapy, including any long-acting treatment provided during inpatient stay for fracture
 - Dispensed prescription to treat osteoporosis

Best practices for healthcare professionals

- Prescribe medication to treat osteoporosis. Use of calcium supplements will not meet criteria for the measure.
- Promote the use of remote/mobile dual-energy X-ray absorptiometry (DEXA) scans.
- Collaborate with our designated team of nurses when they send faxes with notification that a patient of yours has recently experienced a fracture. The patient may ask for your help with follow-up care if they have not received a BMD test in the last two years and are not on an osteoporotic medication.
- Encourage your at-risk patients to have a screening before a fracture occurs. Humana pays for a BMD test every two years for qualified patients—generally women older than 65 who are at risk of losing bone mass or are at risk for osteoporosis, and postmenopausal women older than 50 based on risk factors.
- Claims for BMD test should be submitted with an ICD-10 diagnosis code that indicates risk factors exist for osteoporosis. Claims submitted with screening diagnosis codes, such as Z13.820, may cause the claim to be denied.
- For activity before the fracture, submit supplemental data (i.e., medical record) for a BMD test performed within 24 months or osteoporosis therapy medication prescribed within 12 months.
- For osteoporosis medication given to the patient in a clinical setting within the 12 months prior to the fracture, document in the medical record the medication name, the date that it was dispensed, its dosage/strength and administration route. This documentation can then be submitted as supplemental data.

Food and Drug Administration (FDA)-approved osteoporosis therapies

For detailed formulary information, visit [Humana.com/MedicareDrugList](https://www.humana.com/MedicareDrugList).

Bisphosphonates	HCPCS	Formulary coverage
Alendronate tablet		T1
Alendronate 70 mg tablet		NF
Alendronate-cholecalciferol		NF
Ibandronate tablet		T2
Ibandronate 3 mg/3 mL syringe and vial	J1740	T4
Risedronate tablet		T3, DR 35 mg = T4
Zoledronic acid 5 mg/100 mL	J3489	T1
Other agents		
Abaloparatide		T5
Denosumab	J0897	T4
Raloxifene		T3
Teriparatide 600 mcg/2.4 mL		T5
Teriparatide 620 mcg/2.48 mL	J3110	NF
Romosozumab	J3111	NF
Based on 2021 Super National 5 MAPD		

Coding guidance

Supplemental data is accepted for the OMW measure. Documentation of a BMD test completed in any setting in the 180-day (six-month) period after the fracture date or documentation of a dispensed prescription to treat osteoporosis in the 180-day (six-month) period after a fracture date addresses the measure.

Code	Code type	Definition
76977	CPT	Ultrasound bone density measurement and interpretation, peripheral site(s), any method
77078	CPT	Computed tomography, bone mineral density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine)
77080	CPT	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites; axial skeleton (e.g., hips, pelvis, spine)
77081	CPT	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)
77085	CPT	Dual-energy X-ray absorptiometry (DXA), bone density study, one or more sites axial skeleton (e.g., hips, pelvis, spine), including vertebral fracture assessment
77086	CPT	Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)
BP48ZZ1	ICD-10-PCS	Ultrasonography of right shoulder, densitometry
BP49ZZ1	ICD-10-PCS	Ultrasonography of left shoulder, densitometry
BP4GZZ1	ICD-10-PCS	Ultrasonography of right elbow, densitometry
BP4HZZ1	ICD-10-PCS	Ultrasonography of left elbow, densitometry
BP4LZZ1	ICD-10-PCS	Ultrasonography of right wrist, densitometry
BP4MZZ1	ICD-10-PCS	Ultrasonography of left wrist, densitometry
BP4NZZ1	ICD-10-PCS	Ultrasonography of right hand, densitometry
BP4PZZ1	ICD-10-PCS	Ultrasonography of left hand, densitometry
BQ00ZZ1	ICD-10-PCS	Plain radiography of right hip, densitometry
BQ01ZZ1	ICD-10-PCS	Plain radiography of left hip, densitometry
BQ03ZZ1	ICD-10-PCS	Plain radiography of right femur, densitometry
BQ04ZZ1	ICD-10-PCS	Plain radiography of left femur, densitometry
BR00ZZ1	ICD-10-PCS	Plain radiography of cervical spine, densitometry
BR07ZZ1	ICD-10-PCS	Plain radiography of thoracic spine, densitometry
BR09ZZ1	ICD-10-PCS	Plain radiography of lumbar spine, densitometry
BR0GZZ1	ICD-10-PCS	Plain radiography of whole spine, densitometry
Please note: CPT 77082 and ICD-9 Procedure code 88.98 are obsolete codes that are in the HEDIS value set but are no longer recognized by organizations such as the American Medical Association. If received on claims/ encounter submission, they will be denied for payment processing.		

The coding information in this document is subject to changing requirements and should not be relied on as official coding or legal advice. All coding should be considered on a case-by-case basis and supported by medical necessity and appropriate documentation in the medical record.

NCQA copyright notice and disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA. © 2024 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The full text of this notice and disclaimer is available [here](#):

<https://apps.humana.com/Marketing/Documents.asp?q=qN9cvWvxD83ulyagkCLvaA%3d%3d>